How Merck KgaA’s Life Science Unit Is Riding The Crest Of The Gene Therapy Wave

Udit Batra, member of Merck KGaA's executive board and CEO, life science, tells Scrip in an interview how the company is building on its play in the hot gene therapy area. Batra also outlines how the life science unit’s industry leading e-commerce platform already has the performance "of the level of Amazon or Alibaba" for the scientific space.

Udit Batra
UDIT BATRA, MEMBER OF MERCK'S EXECUTIVE BOARD AND CEO LIFE SCIENCE

Merck KGAA, which has been involved in gene and cell therapy manufacturing tools and services for close to three decades, is ramping up to tap into emerging opportunities in these exciting new areas of medicine.

The German multinational, which has been building on the expertise that the $17bn acquisition of Sigma-Aldrich brought with it in areas like gene editing, has recently been granted

More from Business

More from Scrip